Celltrion Pharm Inc.
KOSDAQ
₩39,400.00
-1.50%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Moderate debt: debt-to-equity of 0.82.
- Comfortable interest cover: operating profit covers interest about 5.2 times.
- Net profit margin is 9%.
- Profit has compounded about 143% a year over five years.
- Sales have compounded about 35% a year over five years.
!Watch-points
- Return on equity is on the lower side at 7%.
- Return on capital employed is on the lower side at 6.5%.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
0.75
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
3 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₩1조 7,438억
Current Price₩ 39,400.00
High / Low₩ 78,300.00 / 0.00
Stock P/E67.35
Book Value₩ 8,402.56
ROCE6.51%
ROE6.97%
Debt to Equity0.82
Current Ratio1.25
EPS₩ 585.00
PAT Margin8.97%
ICR5.16
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity